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To determine the incidence of cardioversion-induced
ventricular arrhythmias in patients with therapeutic serum
levels of digoxin, 19 patients (average age [± standard
deviation] 61 ± 12 years) undergoing elective direct cur-
rent cardioversion for atrial fibrillation were studied.
Only patients with therapeutic serum digoxin levels(range
0.5 to 1.9 nglml; mean 1.1 ± 0.5) at the time of car-
dioversion were included . Patients with acute myo-
cardial ischemia or unstable angina, serious electrolyte
disturbance or those requiring class I antiarrhythmic
agents for control of ventricular or supraventricular ar-
rhythmias were excluded.
Ambulatory electrocardiograms were recorded for 24
hours before and 6 hours after cardioversion. No patient
developed malignant ventricular arrhythmias (ventric-
ular triplets or tachycardia) in the immediate 3 hour
period after cardioversion. Furthermore, there were no
Electrical cardioversion in patients with digitalis toxicity is
often complicated by a variety of arrhythmias including
ventricular tachycardia and fibrillation. Moreover, once in-
itiated, these arrhythmias are frequently difficult to termi-
nate . Concern regarding shock-induced arrhythmias in dig-
italized patients has led to the clinical practice of withholding
digitalis therapy 24 to 48 hours before cardioversion, re-
gardless of the serum level of digoxin (1,2). However , for
some patients , this practice may lead to a delay in perform-
ance of cardioversion, an unwanted increase in ventricular
rate in patients with supraventricular tachyarrhythmias or
a deterioration in left ventricular performance in patients
with congestive heart failure.
Although the exact mechanisms are unknown, current
clinical and experimental evidence suggests that the inci-
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significant (p < 0.05) differences in the frequency of
ventricular premature beats or couplets before and after
cardioversion. To determine whether the level of serum
digoxin or the strength of the applied shock had a sig-
nificant effect on the development of postcardioversion
arrhythmias, the change in frequency of single prema-
ture ventricular beats after cardioversion was compared
with the serum digoxin level (nglml) and the applied
energy level (joules) by means of linear regression anal-
ysis. There was no significant (p < 0.05) relation between
these variables.
These findings suggest that patients with therapeutic
serum levelsof digoxin may safely undergo cardioversion
without the concomitant use of class I antiarrhythmic
agents.
(J Am Coil Cardiol 1985;5:882-8)
denee of postshock arrhythmias is related to the degree of
digitalis excess (2) as well as the strength of the delivered
current (3). However, the incidence of postcardioversion
arrhythmias in patients with digoxin levels within the ther-
apeutic range is not known. Indeed , there is good experi-
mental evidence (4) to suggest that nontoxic doses of dig-
italis do not lead to an increase in postshock ventricular
arrhythmias. Further , the results of a previous clinical study
(5) indicate that cardioversion is safe in patients with "clin-
ically" therapeutic levels of digox in. However, more than
80% of the patients in the latter study were taking quinidine
at the time of the cardioversion , which might have masked
the development of postshock ventricular arrhythmias.
To test the hypothesis that cardioversion is safe in dig-
italized patients , we examined the change in frequency of
postcardioversion ventricular arrhythmias in patients with
therapeutic serum digoxin levels. None of the patients in
our study were taking class I (Vaughan Williams classifi-
cation [6]) antiarrhythmic agents at the time of cardiover-
sion. In addition, we examined the relation between the
change in frequency of postshock ventricular premature beats
and I) the serum digoxin level and 2) the strength of the
applied shock.
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Study patients. We studied all patients receiving long-
term oral digoxin therapy who were undergoing elective
direct current cardioversion for atrial fibrillation at the San
Diego Veterans Administration Medical Center between
February and November of 1983, except those with the
following exclusion criteria: I) acute myocardial infarction
or ischemia or unstable angina. 2) digoxin levels beyond
the therapeutic range (>2 ng/ml)* and 3) use of concurrent
antiarrhythmic agents for control of either supraventricular
or ventricular arrhythmias . A total of 20 patients were en-
tered into the study. However. one patient was excluded
because the electrocardiographic tape recorder malfunc-
tioned; hence, the study comprises the remaining 19 patients.
Protocol. All subjects received anticoagulation with
warfarin sodium (Coumadin) to adjust the prothrombin time
to between 1.5 and 2.0 times the control value for 2 weeks
before and 7 days after cardioversion. On the day before
cardioversion, each patient's serum electrolyte and digoxin
levels were measured. Patients with digoxin levels greater
than ?O ng/ml at this time were excluded from the study.
Continuous ambulatory electrocardiographic monitoring was
performed for 23 ± 2 hours (mean ± I SO) before and 7
± I hours after cardioversion , using a two channel (monitor
leads VI and V2) tape recorder (Avionics Electocardiore-
corder model 445 , Del Mar Avionics) . Cardioversion was
performed using anteroposterior paddles after the patient
was sedated with intravenous methohexital sodium (1 to 2
mg/kg) . The patient was disconnected from the electrocar-
diographic tape recorder monitor just before cardioversion,
and subsequently reconnected immediately afterward. In the
interim period, the patient's rhythm was continuously re-
corded using a single lead electocardiogram (MCL 1 lead).
Serum digoxin, electrolyte and calcium levels were drawn
immediately after cardioversion; only those results obtained
at the time of cardioversion were used for subsequent data
analysis . Patients with digoxin levels greater than 2.0 ng/ml
at the time of cardioversion were retrospectively excluded
from the study .
Decisions regarding digoxin dose, timing of cardiover-
sion, use of additional antiarrhythmic agents after cardio-
version and all other aspects of patient management were
made independently by the physicians caring for the patient.
Data analysis. All electrocardiographic tapes were printed
at 30 times real time on an American Edwards " Eliminator"
cardiac scanner and reviewed by one of us. When questions
arose regarding the nature of a particular beat or beats , tapes
were scanned in real time on an Avionics dynamic electro-
cardioscanner (model 660A. Del Mar Avionics ). We clas-
. *As ~ re~ull of our screening before cardioversion, only one patient
With a digoxin level gr.ea~er than 2.0 ng/ml was studied; this patient de-
velo~d one short self-limited burst of ventricular tachycardia 3 hours after
cardioversion,
sified wide complex beats as either ventricular in origin or
" aberrant," according to published guidelines (7,8). To
elimin~te bias in favor of our hypothesis, when the origin
of a WIde complex beat could not be classified using real
time scanning, the beat was considered to be aberrant if it
~curred before cardioversion, and ventricular in origin if
Itoccurred after cardioversion. Ventricular arrhythmias were
classified into the following categories: single premature
beats, couplets, triplets and tachycardia.
To account for temporal variability in the frequency of
ventricular arrhythmias. we compared the change in fre-
quency of these arrhythmias before and after cardioversion
by dividing the electrocardiographic monitor data base into
three separate 6 hour periods. Period I was recorded the
day before cardioversion during the same time of day as
period 3 (see later). Period 2 was recorded during the 6
hours immediately before cardioversion. Period 3 was re-
corded during the 6 hours immediately after cardioversion.
To .exclu~e the possibility that the length of the monitoring
penod might have obscured changes in the frequency of
arrhythmias immediately after cardioversion, we also com-
pared the frequency of ventricular premature beats and cou-
plets during the first hour after cardioversion with their
frequency during periods I and 2.
Statistical analysis. The mean hourly frequency of sin-
gle ventricular premature beats, couplets, triplets and tachy-
cardia was determined for periods I to 3. Because of the
infrequency of the lattertwo arrhythmias. only the postshock
change in frequency of single premature ventricular beats
and couplets was subjected to statistical analysis. We used
the Wilcoxon rank sum test to compare the incidence of
ventricular premature beats and couplets in periods I and 2
with their incidence during period 3, as well as during the
first hour after cardioversion . Statistical significance was
defined at the p < 0.05 level.
To determine whether the serum digoxin level or the
strength of the shock applied had a significant effect on the
development of postcardioversion premature ventricular beats,
we performed linear regression analysis using the Pearson
product moment coefficient. For this analysis, the mean
hourly frequency of ventricular premature beats for periods
I to 3 was normalized (logl o [I + premature ventricular
beats]) and converted to a percent change: ([X - Y l/X)
x lOa. where X equals the incidence of mean premature
v~ntricular beats after cardioversion and Y equals the in-
cidence of premature ventricular beats before cardioversion.
Statistical significance was again defined at the p < 0.05
level .
Results
Clinical data (Table 1). Eighteen patients had known
organic heart disease, and one patient had "lone" atrial
fibrillation. Although no patients were receiving class I an-
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Table 1. Clinical Data in 19 Patients
{3-Adrenergic Serum Serum
Blocking Digoxin Serum K+ Ca++ Total Energy
Case Age (yr) Etiology CHF Agent (ng/ml) (mEqlliter) (mg/dl) Delivered (J)
I 45 HTN 0.8 4.2 8.9 150
2 57 EtOH 1.1 3.6 8.6 375
3 53 "Lone" 0.9 3.8 9.2 300
4 63 RHD 1.0 4.5 9.4 150
5 58 HTN 0.5 4.3 8.8 570
6 45 HTN 1.3 3.5 9.3 350
7 69 IHD {3' 0.7 3.3 8.9 375
8 60 HTN 1.0 3.1 8.3 840
9 56 HTN 1.3 3.2 8.1 570
10 66 HTN {32 0.6 3.9 8.8 350
II 73 IHD + 1.7 4.6 8.9 300
12 36 EtOH 1.5 4.2 9.1 100
13 69 HTN 1.0 3.8 9.2 100
14 55 IHD {33 1.2 3.9 7.3 400
15 59 IHD 1.4 3.6 8.9 375
16 83 MVP 0.6 3.7 8.1 125
17 85 IHD 0.7 4.2 8.4 100
18 74 HTN 1.9 5.0 8.4 100
19 57 CM 0.9 4.6 7.9 575
Mean 61 ± 12 1.1 ± 0.5 3.9 ± 0.5 8.4 ± 1.1 327 ± 206
± I SD
{3' = propranolol. 10 mg three times a day; {32 = metoprolol, 50 mg twice a day; {33 = atenolol, 50 mg once daily; CHF = congestive heart failure;
CM = cardiomyopathy; EtOH = alcoholic; HTN = hypertension; IHD = ischemic heart disease; "Lone" = idiopathic; MVP = mitral valve prolapse;
RHD = rheumatic heart disease; SD = standard deviation; total energy delivered = cumulative (stored) energy; + = present; - = not present.
tiarrhythmic drugs before cardioversion, three patients were
receiving beta-adrenergic blocking agents (two for control
of angina and one for control of hypertension). Precardio-
version long-term oral maintenance doses of digoxin ranged
from 0.125 to 0.5 mg daily, with an interval of 12 to 48
hours between the last dose of digoxin administered and
direct current cardioversion; no further digoxin was admin-
istered during the 6 hour postcardioversion monitoring pe-
riod. The mean serum digoxin level drawn immediately after
cardioversion was 1.1 ± 0.5 ng/ml (range 0.5 to 1.9). Mean
values for serum potassium and calcium drawn immediately
after cardioversion were 3.9 ± 0.5 mEq/liter (range 3.1 to
5.0) and 8.4 ± 1.1 mg/dl (range 7.3 to 9.9), respectively.
The patients received an average of2.4 ± 1 shocks .. the
mean stored cumulative energy given was 327 ± 206 J
(range 100 to 840). Among the 19 patients undergoing elec-
tive cardioversion, 16 attempts were initially successful.
One patient experienced reversion to atrial fibrillation during
the 24 hour follow-up period.
Development of postcardioversion ventricular ar-
rhythmias. The incidence of ventricular premature beats
and couplets is presented in Table 2. Figure 1 depicts the
data grouped as the mean hourly frequency of episodes of
ventricular couplets and single premature ventricular beats
for periods I to 3. Although interpatient variability was
great, there was a trend toward a decrease in all ventricular
arrhythmias after cardioversion. There was no statistically
significant difference in premature ventricular beats or cou-
plets when period I or period 2 was compared with period
3. Further, there was no statistically significant difference
in the frequency of these arrhythmias during the first hour
after cardioversion when compared with period I or 2.
As indicated previously, since there were only three
patients (Cases 2, 18 and 19) with ventricular triplets and
one patient (Case 2) with ventricular tachycardia before
cardioversion, the pre- and postcardioversion frequency of
these arrhythmias was not subjected to statistical analysis.
None of these three patients developed ventricular tachy-
cardia after cardioversion, and only one (Case 18) developed
ventricular triplets during the fourth hour of postshock mon-
itoring; however, for this patient, the frequency of triplets
was similar before and after cardioversion. None of the
remaining 16 patients developed ventricular triplets or
tachycardia during the postcardioversion monitoring period.
Influence of level of serum digoxin and strength of
the delivered shock. To determine whether the serum di-
goxin level influenced the development of postcardioversion
premature ventricular beats, we examined the relation be-
tween the percent change in frequency of postshock ven-
tricular premature beats and the serum digoxin level by
means of linear regression analysis (Fig. 2). The correlation
coefficients relating the change in frequency of ventricular





Table 2. Cardioversion Data in Patients With VentricularPremature Beats and Couplets
Premature Beats Couplets
Monitor Period Monitor Period
Case 2 3 2 3
I 2 ± 2 9 ± 4 0.3 ± 0.5 0.3 ± 0.7 4 ± 3 0
2 155 ± 240 6 ± 3 5 ± 2 4 ± 7 0 0
3 43 ± 13 25 ± 18 81 ± 47 0 0.3 ± 0.5 0
4 5 ± 4 12 ± 4 2 ± I 0.5 ± 0.8 2 ± I 0
5 12 ± 5 16 ± 2 38 ± 2 0.2 ± 0.4 0.3 ± 0.7 0.6 ± 0.5
6 2 ± 2 2 ± 2 4 ± 3 0 0.2 ± 0.4 0
7 24 ± 12 16 ± 12 II ± 10 * * *
8 I ± I I ± I 3 ± 2 0 0 0.5 ±
9 8 ± 8 4 ± 3 6 ± 2 0.2 ± 0.4 0 0
10 41 ± 5 144 ± 28 108 ± 45 0 0.2 ± 0.4 I
II 35 ± 20 8 ± 6 15 ± 5 0.2 ± 0.4 0 0
12 0.2 ± 0.4 0 0.2 ± 0.4 * * *
13 I ± I 6 ± 5 0.3 ± 0.5 * * *
14 76 ± 30 86 ± 74 25 ± 43 0 0.3 ± 0.4 0
15 40 ± 7 30 ± 10 32 ± 6 0 0.3 ± 0.4 0.2 ± 0.4
16 57 ± 25 63 ± 80 6 ± 2 0.5 ± 0.5 0.7 ± 0.7 0.2 ± 0.4
17 26 ± 13 66 ± 34 108 ± 74 I ± I 2 ± 3 I ± I
18 39 ± 21 82 ± 44 42 ± 34 5 ± 5 24 ± 14 0.5 ± 0.8
19 I ± 2 9 ± 10 I ± 2 * *
*Patients without ventricular couplets during the monitoring period. Data areexpressed as mean hourly frequency ± I standard deviation.
premature beats for period I versus period 3 and period 2
versus period 3 against the level of serum digoxin were
weakly positive (r = 0.13 and 0.22, respectively). This
relation was not significant for period I versus period 3 or
period 2 versus period 3 (p = 0.46 and 0.36, respectively).
In addition, we used linear regression analysis to examine
the relation between the change in frequency of posts hock
premature beats and the strength of the shock (cumulative
joules) given. Figure 3 depicts the regression lines for this
relation. There was a small positive correlation between the
strength of the shock and the development of postcardio-
version premature ventricular beats (r = 0.43 for period I
versus period 3 and r = 0.34 for period 2 versus period 3).
The correlation was nearly significant for period I versus 3
(p = 0.06), but was not significant for period 2 versus
period 3 (p = 0.15).
Discussion
In this study, we examined the incidence of pre- and
postshock ventricular arrhythmias in patients with thera-
peutic serum digoxin levels who were undergoing elective
cardioversion for atrial fibrillation. None of our patients
developed malignant ventricular arrhythmias (defined as
ventricular triplets or tachycardia) during the 3 hour period
immediately after cardioversion, and there was no signifi-
cant increase in the frequency of single premature ventric-
ular beats or couplets during this time. The present inves-
tigation differs importantly from previously reported studies
(2,5) because none of our patients was taking class I an-
tiarrhythmic drugs (6) during the study period. In addition,
we employed a more extensive electrocardiographic mon-
itoring period than has been previously reported (5).
Postcardioversion ventricular arrhythmias with toxic
digoxin levels. The concept that cardioversion is dangerous
in patients receiving digitalis stems from both clinical
(1,2,9-11) and experimental studies (12). In patients with
digitalis toxicity, sustained ventricular tachycardia or ven-• = /5
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Figure 1. Mean hourly frequency of premature ventricular beats
and couplets before and after cardioversion. There was no signif-
icant (NS) difference in the mean hourly frequency of premature
ventricular beats or episodes of couplets when comparing period
I with period 3, or period 2 with period 3.
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tricular fibrillation, or both, has occurred immediately after
cardioversion (1,2,9,10), or in one study (1), up to 3 hours
postshock. Moreover, the incidence of shock-induced ar-
rhythmias appears to be related to the intensity of the stim-
ulus (II) and may be related to the degree of digitalis toxicity
(2). Similar observations were reported by investigators us-
ing canine models (3,12). Toxic or nearly toxic doses of
rapidly acting digitalis glycosides have been shown to mark-
edly reduce the energy threshold required to induce ven-
tricular arrhythmias (12), as well as increase the duration
Figure 2. Relation between the development of postcardioversion
premature ventricular beats (PVB's) in period 3, expressed as a
percent change from baseline values in period 1 or 2 and the serum
digoxin level (see text).
Figure 3. Relation between the development of postcardioversion
premature ventricular beats (PVB's) in period 3, expressed as a
percent change from baseline values in period 1or 2 and the applied
energy level (see text).
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of postshock arrhythmias (3). While the mechanism for
these postshock arrhythmias has not been fully elucidated,
it may be related to release of norepinephrine from cardiac
nerve terminals (3) or possibly potassium leakage from cells
as a result of shock-induced interruption of the membrane
transport system (12,13). Although the relation between the
development of malignant ventricular arrhythmias and dig-
italis toxicity is well established, this relation is less clearly
defined for nontoxic doses of digitalis. Indeed, in therapeutic
doses, digitalis preparations have been shown to reduce
ventricular arrhythmias (14,15).
Postcardioversion ventricular arrhythmias with ther-
apeutic digoxin levels. The evidence that therapeutic doses
of digoxin do not cause an increase in postshock ventricular
arrhythmias is suggested both by experimental (4) and by
clinical (5) observations. Using a canine model, Ditchey
and Curtis (4) demonstrated that the risk of ventricular ar-
rhythmia after transthoracic electrical shocks was not sig-
nificantly affected by pretreatment with apparent nontoxic
doses of digoxin. In a subsequent clinical study by Ditchey
and Karliner (5), the incidence of postcardioversion ventric-
ular arrhythmias was examined in 21 patients with "clini-
cally therapeutic" digoxin levels (range 0.1 to 3.0 ng/ml).
Using continuous ambulatory electrocardiographic moni-
toring (range I to 12 hours before and I hour after car-
dioversion), these investigators noted no increase in ven-
tricular arrhythmias after cardioversion. However, 17 of
their 21 patients were taking quinidine at the time of car-
dioversion; therefore, the possibility that quinidine might
have "helped suppress postcardioversion ventricular ar-
rhythmias" was considered.
In the present study, we found no significant difference
in the frequency or severity of pre- and postshock ventricular
arrhythmias in patients with a therapeutic serum digoxin
level, none of whom was taking a class I antiarrhythmic
agent (6) at the time of cardioversion. Moreover, there was
a trend toward a decrease in some postshock ventricular
arrhythmias (Fig. I). In this regard, our data are consistent
with the experimental observations of Ditchey and Curtis
(4) and are in overall agreement with the clinical report by
Ditchey and Karliner (5). Importantly, no patient developed
malignant ventricular arrhythmias during the initial 3 hours
after cardioversion. Although one patient (Case 18) devel-
oped ventricular triplets during the fourth hour of postcar-
dioversion monitoring, the incidence of ventricular triplets
for this patient was similar before and after cardioversion.
Several clinical studies (2, II) suggested that the inci-
dence of shock-induced arrhythmias in digitalized patients
is related to the degree of digitalis toxicity. To determine
whether a relation exists between ventricular arrhythmias
and therapeutic serum digoxin concentrations, we compared
the percent change in postshock ventricular premature beats
with the serum digoxin level by means of linear regression
analysis. This analysis indicated that for values within the
therapeutic range, the serum digoxin level did not have a
significant influence on the development of postcardiover-
sion premature ventricular beats (Fig. 2), a finding that is
also in agreement with the report by Ditchey and Karliner
(5). Previous clinical studies (4) suggested that the extent
of postshock arrhythmias in patients with digitalis toxicity
can be diminished by reducing the strength of the electrical
shock. To determine whether this might also be the case
for patients with therapeutic digoxin levels, we examined
the relation between the development of postcardioversion
premature ventricular beats and the strength (cumulative
joules) of the delivered shock. For patients with therapeutic
digoxin levels, there was a small positive correlation be-
tween the strength of the shock and the development of
premature ventricular beats (r = 0.34 to 0.43). Since there
was a trend toward statistical significance (Fig. 3), it is
possible that a larger study might have disclosed a statis-
tically significant relation.
Our findings support the hypothesis that direct current
cardioversion is safe in patients with therapeutic digoxin
levels. However, none of our patients had acute myocardial
ischemia, severe electrolyte imbalance or was receiving an-
tiarrhythmic drugs for suppression of ventricular arrhyth-
mias. In addition, three of our patients were taking a beta-
adrenergic blocking agent at the time of cardioversion. Con-
ceivably, such a drug might have suppressed postshock ar-
rhythmias. However, the relatively low doses used suggest
that beta-receptor blockade was only partially attained. Since
beta-adrenergic blockers appear to suppress postshock ar-
rhythmias only under conditions of maximal beta-receptor
blockade (3), these patients were included in the present
study.
Methodologic considerations. In a clinical study of this
type, several methodologic difficulties exist with regard to
data analysis. First, it can be difficult to determine from the
surface electrocardiogram whether a given beat is aberrantly
conducted or ventricular in origin (7,8); however, when
doubt existed, we considered the beat aberrant if it occurred
before cardioversion and ventricular in origin if it occurred
after cardioversion. Thus, our decision algorithm would
have biased our results against our hypothesis. Second, one
might argue that by employing 6 hour monitoring periods,
we obscured changes in the frequency of ventricular ar-
rhythmias occurring within the first hour after cardioversion.
We adopted this approach because of the difficulties inherent
in assessing hourly changes in the frequency of ventricular
arrhythmias (16-19). However, to exclude the possibility
that our analysis influenced the statistical outcome, we re-
peated the analysis using a I hour postcardioversion moni-
toring period; the statistical outcome was the same. Lastly,
to account for temporal variations in the frequency of ven-
tricular premature beats and couplets, we compared the change
in frequency of these arrhythmias immediately before and
after cardioversion (period 2 versus period 3) as well as
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during the same time of day before and after cardioversion
(period I versus period 3).
Conclusions. Patients with therapeutic digoxin levels may
safely undergo cardioversion without the concomitant use
of antiarrhythmic agents. Furthermore, our data indicate that
for digoxin values within the therapeutic range, neither the
serum level of digoxin nor the strength of the delivered
shock appears to importantly affect the development of
postcardioversion premature ventricular beats.
We acknowledge the statistical support of Elizabeth Gilpin and the sec-
retarial assistance of Linda McKeller. In addition, we thank Guy Curtis,
MD for his support.
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